## **NEWS**

Contact:
Gualberto Ruaño, M.D., Ph.D.
Genomas, Inc.
860-545.3773

FOR IMMEDIATE RELEASE OCTOBER 4, 2005



## GENOMAS AWARDED SBIR GRANTS TOTALING \$500,000 FROM THE NATIONAL INSTITUTES OF HEALTH IN PARTNERSHIP WITH THE INSTITUTE OF LIVING

**HARTFORD, CT** – Genomas, a biomedical company developing diagnostic and information systems for personalized health, today announced the award of two Small Business Innovation Research (SBIR) Grants through the National Institute of Health. The grants, in the amount of \$500,000, were awarded by the National Institute of Mental Health for the development of physiogenomics arrays and diagnostics for clinical neuropsychiatry. The grants allow Genomas to develop its physiogenomics technology and advance its deployment into high impact areas of application of personalized medicine.

Genomas will be collaborating with Hartford Hospital's Institute of Living (IOL) on both grants. Under these programs, Genomas physiogenomics technology will be interfaced with clinical studies on drug-induced metabolic syndrome and functional imaging of the brain. The results have implications for the diagnosis and safer treatment of schizophrenia, mood disorders and Alzheimer's disease. Various drugs used in psychiatry result in drug-induced metabolic syndromes, including obesity, diabetes, and cardiovascular disease. At the same time, functional imaging is opening for the first time metabolic aspects of psychiatric disease amenable to prognostic DNA typing.

In announcing the awards, Gualberto Ruaño, M.D., Ph.D., President and CEO of Genomas and Director of Cardiovascular Genetics Research at Hartford Hospital commented: "By interfacing complex psychiatric phenomena with the physiogenomics approach, the variability observed in clinical practice can be translated into fundamental discoveries of disease mechanism and diagnosis. Drug Induced Metabolic Syndrome in particular is a high impact medical need for drug safety, and complements our programs on obesity-induced metabolic syndromes. Moving forward, our physiogenomic technology will be lent a major impetus on its development by interfacing it with functional imaging and MRI to open the new vista of genomic imaging. The ensemble of several DNA markers into multi-analyte devices combined with mathematical algorithms delivering predictive and prognostic information to the physician about the individual patient is the foundation of our diagnostic strategy."

Laurine Bow, Ph.D., Vice President for Research at Hartford Hospital added: "The IOL and Hartford Hospital have received \$10,000,000 in research awards for neuropsychiatry in the last year. We are pleased that this success is now mirrored in the awarded SBIR grants with Genomas, which pave the way for developing intellectual property and commercialization revenue from fundamental discoveries at the IOL and Hartford Hospital."

(more)

Harold I. Schwartz, M.D., Psychiatrist-in-Chief at the IOL and Vice President for Behavioral Health at Hartford Hospital observed, "Of all medical disciplines psychiatry is one of the most to benefit from personalized medicine based on DNA typing. The end result is double prevention management, which includes both treatment of disease through its earliest possible diagnosis, and treatment with psychotropic agents while avoiding metabolic adverse reactions. Double prevention represents a new paradigm in the new field of personalized medicine being pioneered in these SBIR programs of Genomas with our IOL Faculty, Dr. John W. Goethe, Director of the Burlingame Center for Psychiatric Research and Education, and Dr. Godfrey Pearlson, Director of the Olin Neuropsychiatry Research Center."

## **ABOUT GENOMAS**

Genomas Inc. is a biomedical company advancing personalized healthcare with revolutionary diagnostic PhysioType™ systems to treat obesity- and drug-induced metabolic syndromes in cardiovascular and psychiatric medicine. PhysioType systems provide physicians with the unprecedented capability to prescribe personalized drug treatments avoiding side effects and to recommend highly effective preventive exercise and diet programs for each patient. Genomas is located in Hartford, CT. on the campus of Hartford Hospital with which it has established a research and development partnership in personalized medicine. For more information please access the company's web site at <a href="https://www.genomas.net">www.genomas.net</a>

## ABOUT THE INSTITUTE OF LIVING AT HARTFORD HOSPITAL

Founded in 1822, The Institute of Living (IOL) was one of the first mental health centers in the United States, and the first hospital of any kind in Connecticut. Today, as part of Hartford Hospital, it is one of America's leading centers for comprehensive patient care, research and education in the fields of behavioral, psychiatric, and addiction disorders. Affiliated with Yale and the University of Connecticut, and close collaborator with the Connecticut Department of Mental Health and Addiction Services, the IOL has training programs in psychiatry, psychology, social work, nursing, and rehabilitation. As a research center, The Institute of Living conducts clinical trials of investigational new drugs and is a leader in outcome studies. For more information please access the IOL's web site at www.instituteofliving.org

###